Mobile

A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) wi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017197-21

A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) with Overactive Bladder (OAB) Protocol for Phase I Study of solifenacin succinate suspension Single ascending dose PK study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the PK of solifenacin succinate suspension after single-dose administration at different dose levels in children and adolescents with OAB.

Critère d'inclusion

  • Overactive Bladder

Liens